The Patent Finder

BioNTech SE

120 patents currently held · Updated Nov 18, 2026
25 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 3 name spellings.

14
Ending by 2030
Jan 2027
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Nov 30, 2026
    The maintenance fee for Particles comprising a shell with RNA (US 11,660,338) comes due Nov 30, 2026. Unpaid by Jun 1, 2027, it lapses early.
  • 1 fee due Dec 13, 2026
    The maintenance fee for Compositions and Methods for Diagnosis and Treatment of Cancer (US 11,673,939) comes due Dec 13, 2026. Unpaid by Jun 14, 2027, it lapses early.
  • 3 fees due Jan 7 to 28, 2027 · next Jan 7
  • 2 fees due Feb 1 to 6, 2027 · next Feb 1
  • 1 fee due Mar 19, 2027
    The maintenance fee for Human Monoclonal Antibodies to Ganglioside GD2 (US 11,760,809) comes due Mar 19, 2027. Unpaid by Sep 20, 2027, it lapses early.
  • 4 fees due Apr 1 to 29, 2027 · next Apr 1
  • 3 fees due May 3 to 26, 2027 · next May 3
  • 4 fees due Jul 9 to 23, 2027 · next Jul 9
  • 5 fees due Sep 3 to 29, 2027 · next Sep 3
  • 3 fees due Oct 9 to 26, 2027 · next Oct 9

Which patents, and when each one lapses · Pro

Recent changes

  • 4 of the patents on this record were granted since Aug 20, 2026
  • 3 terms have ended since Aug 20, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 7,875,424Identification of Tumour-Associated Cell Surface Antigens for Diagnosis and Therapy
In force
 · High confidence
In forceHigh confidence
US 8,178,653Recombinant Vaccines and Use Thereof
In force
 · High confidence
In forceHigh confidence
US 9,090,940Identification of Surface-Associated Antigens for Tumor Diagnosis and Therapy
In force
 · Medium confidence
In forceMedium confidence
US 11,020,477RNA Vaccines
In force
 · Medium confidence
In forceMedium confidence
US 10,253,373Identification of Tumor-Associated Markers for Diagnosis and Therapy
In force
 · High confidence
In forceHigh confidence
US 8,258,258Dimeric or multimeric microproteins
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,008,550Use of RNA for reprogramming somatic cells
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,446,040Substituted imidazoquinolines
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,908,880Substituted imidazoquinolines
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,349,558Detection of Individual T-Cell Reaction Patterns Against Tumor-Associated Antigens (TAA) in Tumor Patients as a Basis for the Individual Therapeutic Vaccination of Patients
In force
 · High confidence
In forceHigh confidence
10 of 120 patents shown.
Pro members see all 120.
Pro members: see all 120 patents
Also on record, not counted in the 120: 25 patents in force now held by others · 7 lapsed for an unpaid fee · 21 ended at full term · 1 past the fee grace period. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

84 pending · 24 abandoned · 15 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited